Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

6.165 +0.205 (+3.44%)
Streaming Delayed Price Updated: 2:11 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Earnings Preview: Amicus Therapeutics
Via Benzinga
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
Via Benzinga
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Recap: Amicus Therapeutics Q3 Earnings
Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
From Amicus Therapeutics, Inc.
Via GlobeNewswire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday. 
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
  PayPal Holdings, Inc. (NASDAQ: PYPL) rose 12% to $100.35 in pre-market trading after the company reported better-than-expected Q2 results and raised FY22 EPS guidance. 
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Short Volatility Alert: Amicus Therapeutics, Inc.
On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS